お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
916407

抗うつ薬の世界市場:産業動向、シェア、規模、成長、機会、および予測(2019年~2024年)

Depression Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024

出版日: | 発行: IMARC Services Private Limited | ページ情報: 英文 109 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.58円
抗うつ薬の世界市場:産業動向、シェア、規模、成長、機会、および予測(2019年~2024年)
出版日: 2019年10月20日
発行: IMARC Services Private Limited
ページ情報: 英文 109 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗うつ薬市場は、2019年から2024年の間に2.5%のCAGRで成長する見通しです。

当レポートは世界の抗うつ薬市場について調査しており、産業動向、市場予測、薬剤クラス・疾患タイプ・薬剤タイプ・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 序文

第2章 範囲および調査方法

  • 調査の目的
  • 利害関係者
  • 情報源
    • 一次情報源
    • 二次情報源
  • 市場予測
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 予測方法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主な産業動向

第5章 世界市場

  • 市場概況
  • 市場実績
  • 薬剤クラス別
  • 疾患タイプ別
  • 薬剤タイプ別
  • 流通チャネル別
  • 地域別

第6章 市場分析:薬剤クラス別

  • 非定型抗精神病薬
  • セロトニン・ノルアドレナリン再取り込み阻害薬(SNRI)
  • 選択的セロトニン再取り込み阻害剤(SSRI)
  • 中枢神経系(CNS)刺激薬
  • 三環系抗うつ薬
  • モノアミン酸化酵素阻害薬
  • その他

第7章 市場分析:疾患タイプ別

  • 大鬱病性障害
  • 強迫性障害
  • 全般性不安障害
  • パニック障害
  • その他

第8章 市場分析:薬剤タイプ別

  • ジェネリック医薬品
  • ブランド医薬品

第9章 市場分析:流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

第10章 市場分析:地域別

  • 北米
  • 欧州
  • アジア太平洋地域
  • 中東・アフリカ
  • ラテンアメリカ

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 市場機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 業界内の競争
  • 新規参入の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 企業プロファイル
    • 大塚製薬株式会社
    • Pfizer
    • Eli Lilly and Company
    • AstraZeneca
    • Novartis
    • Bristol-Myers Squibb
    • GlaxoSmithKline
    • 武田薬品工業株式会社
    • Allergan
    • Johnson & Johnson
    • Zhejiang NHU Company Ltd
    • Sebela Pharmaceuticals
図表

List of Figures

  • Figure 1: Global: Depression Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Depression Drugs Market: Sales Value (in Billion US$), 2013-2018
  • Figure 3: Global: Depression Drugs Market: Breakup by Drug Class (in %), 2018
  • Figure 4: Global: Depression Drugs Market: Breakup by Disorder Type (in %), 2018
  • Figure 5: Global: Depression Drugs Market: Breakup by Drug Type (in %), 2018
  • Figure 6: Global: Depression Drugs Market: Breakup by Distribution Channel (in %), 2018
  • Figure 7: Global: Depression Drugs Market: Breakup by Region (in %), 2018
  • Figure 8: Global: Depression Drugs Market Forecast: Sales Value (in Billion US$), 2019-2024
  • Figure 9: Global: Depression Drugs Industry: SWOT Analysis
  • Figure 10: Global: Depression Drugs Industry: Value Chain Analysis
  • Figure 11: Global: Depression Drugs Industry: Porter's Five Forces Analysis
  • Figure 12: Global: Depression Drugs (Atypical Antipsychotics) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 13: Global: Depression Drugs (Atypical Antipsychotics) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 14: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 15: Global: Depression Drugs (Serotonin-Norepinephrine Reuptake Inhibitors) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 16: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 17: Global: Depression Drugs (Selective Serotonin Reuptake Inhibitors) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 18: Global: Depression Drugs (Central Nervous System (CNS) Stimulant) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 19: Global: Depression Drugs (Central Nervous System (CNS) Stimulant) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 20: Global: Depression Drugs (Tricyclic Antidepressants) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 21: Global: Depression Drugs (Tricyclic Antidepressants) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 22: Global: Depression Drugs (Monoamine oxidase inhibitors) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 23: Global: Depression Drugs (Monoamine oxidase inhibitors) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 24: Global: Depression Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 25: Global: Depression Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 26: Global: Depression Drugs (Major Depressive Disorder) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 27: Global: Depression Drugs (Major Depressive Disorder) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 28: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 29: Global: Depression Drugs (Obsessive-Compulsive Disorder) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 30: Global: Depression Drugs (Generalized Anxiety Disorder) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 31: Global: Depression Drugs (Generalized Anxiety Disorder) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 32: Global: Depression Drugs (Panic Disorder) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 33: Global: Depression Drugs (Panic Disorder) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 34: Global: Depression Drugs (Other Disorder Types) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 35: Global: Depression Drugs (Other Disorder Types) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 36: Global: Depression Drugs (Generic Drugs) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 37: Global: Depression Drugs (Generic Drugs) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 38: Global: Depression Drugs (Branded Drugs) Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 39: Global: Depression Drugs (Branded Drugs) Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 40: Global: Depression Drugs Market: Sales through Hospital Pharmacies (in Million US$), 2013 & 2018
  • Figure 41: Global: Depression Drugs Market Forecast: Sales through Hospital Pharmacies (in Million US$), 2019-2024
  • Figure 42: Global: Depression Drugs Market: Sales through Retail Pharmacies (in Million US$), 2013 & 2018
  • Figure 43: Global: Depression Drugs Market Forecast: Sales through Retail Pharmacies (in Million US$), 2019-2024
  • Figure 44: Global: Depression Drugs Market: Sales through Online Pharmacies (in Million US$), 2013 & 2018
  • Figure 45: Global: Depression Drugs Market Forecast: Sales through Online Pharmacies (in Million US$), 2019-2024
  • Figure 46: Global: Depression Drugs Market: Sales through Other Distribution Channels (in Million US$), 2013 & 2018
  • Figure 47: Global: Depression Drugs Market Forecast: Sales through Other Distribution Channels (in Million US$), 2019-2024
  • Figure 48: North America: Depression Drugs Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 49: North America: Depression Drugs Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 50: Europe: Depression Drugs Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 51: Europe: Depression Drugs Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 52: Asia Pacific: Depression Drugs Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 53: Asia Pacific: Depression Drugs Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 54: Middle East and Africa: Depression Drugs Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 55: Middle East and Africa: Depression Drugs Market Forecast: Sales Value (in Million US$), 2019-2024
  • Figure 56: Latin America: Depression Drugs Market: Sales Value (in Million US$), 2013 & 2018
  • Figure 57: Latin America: Depression Drugs Market Forecast: Sales Value (in Million US$), 2019-2024

List of Tables

  • Table 1: Global: Depression Drugs Market: Key Industry Highlights, 2018 and 2024
  • Table 2: Global: Depression Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2019-2024
  • Table 3: Global: Depression Drugs Market Forecast: Breakup by Disorder Type (in Million US$), 2019-2024
  • Table 4: Global: Depression Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2019-2024
  • Table 5: Global: Depression Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2019-2024
  • Table 6: Global: Depression Drugs Market Forecast: Breakup by Region (in Million US$), 2019-2024
  • Table 7: Global: Depression Drugs Market Structure
  • Table 8: Global: Depression Drugs Market: Key Players
目次
Product Code: SR1019E85_Report

The global depression drugs market is expected to grow at a CAGR of 2.5% during 2019-2024. Depression drugs, or antidepressants, are a range of medications that are consumed for the treatment of mental disorders such as social anxiety and depression. They are intended to balance the functioning of neurotransmitters such as serotonin in the brain, thus controlling the mood and emotions of the patient. Depression and related mental disorders are characterized by the absence of positive emotions, constant low mood and numerous cognitive, physical, behavioral and emotional symptoms. These drugs can assist in relieving the symptoms of anxiety, seasonal affective disorder and dysthymia. Antidepressant medications include the use of Selective Serotonin Reuptake Inhibitors (SSRIs), atypical antidepressants and Monoamine Oxidase Inhibitors (MAOIs) that are most effective when consumed along with regular therapeutic sessions.

The growing prevalence of major depressive disorders across the globe is the key factor driving the growth of the market. Depression in adolescents and adults is increasing due to several factors including social isolation, improper dietary habits and work-life imbalance. Furthermore, the increasing geriatric population across the globe that suffers from isolation from family and friends, along with other health-related issues, are also augmenting the growth of the market. However, there is rising awareness about depression as a psychological issue and methodologies to cure it, which has enhanced the adoption of these drugs among patients of all age groups. Additionally, the emergence of novel techniques for the development of antidepressants with minimal side-effects and prolonged results, along with the acceptance of new medications, is also favoring the market growth. For instance, psychedelics such as ketamine are widely considered to ease the symptoms of depression and provide relief.

IMARC Group's latest report provides a deep insight into the global depression drugs market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter's five forces analysis, value chain analysis, etc. This report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the depression drugs market in any manner.

Report Coverage:

Historical, Current and Future Market Trends

Market Breakup by Drug Class:

  • Atypical Antipsychotics
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
  • Selective Serotonin Reuptake Inhibitors (SSRIs)
  • Central Nervous System (CNS) Stimulants
  • Tricyclic Antidepressants
  • Monoamine Oxidase Inhibitors
  • Others

Market Breakup by Disorder Type:

  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others

Market Breakup by Drug Type:

  • Generic Drugs
  • Branded Drugs

Market Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Market Breakup by Region:

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Competitive Landscape

The report has also analyzed the competitive landscape of the market with some of the key players being Otsuka Pharmaceutical, Pfizer, Eli Lilly and Company, AstraZeneca, Novartis, Bristol-Myers Squibb, GlaxoSmithKline, Takeda Pharmaceutical Company, Allergan, Johnson & Johnson, Zhejiang NHU Company Ltd, Sebela Pharmaceuticals, etc.

Key Questions Answered in This Report:

  • How has the global depression drugs market performed so far and how will it perform in the coming years?
  • What are the key regional markets in the global depression drugs industry?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the disorder type?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the global depression drugs industry?
  • What are the key driving factors and challenges in the global depression drugs industry?
  • What is the structure of the global depression drugs industry and who are the key players?
  • What is the degree of competition in the global depression drugs industry?

Table of Contents

1. Preface

2. Scope and Methodology

  • 2.1. Objectives of the Study
  • 2.2. Stakeholders
  • 2.3. Data Sources
    • 2.3.1. Primary Sources
    • 2.3.2. Secondary Sources
  • 2.4. Market Estimation
    • 2.4.1. Bottom-Up Approach
    • 2.4.2. Top-Down Approach
  • 2.5. Forecasting Methodology

3. Executive Summary

4. Introduction

  • 4.1. Overview
  • 4.2. Key Industry Trends

5. Global Depression Drugs Market

  • 5.1. Market Overview
  • 5.2. Market Performance
  • 5.3. Market Breakup by Drug Class
  • 5.4. Market Breakup by Disorder Type
  • 5.5. Market Breakup by Drug Type
  • 5.6. Market Breakup by Distribution Channel
  • 5.7. Market Breakup by Region
  • 5.8. Market Forecast

6. Market Breakup by Drug Class

  • 6.1. Atypical Antipsychotics
    • 6.1.1. Market Trends
    • 6.1.2. Market Forecast
  • 6.2. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
    • 6.2.1. Market Trends
    • 6.2.2. Market Forecast
  • 6.3. Selective Serotonin Reuptake Inhibitors (SSRIs)
    • 6.3.1. Market Trends
    • 6.3.2. Market Forecast
  • 6.4. Central Nervous System (CNS) Stimulants
    • 6.4.1. Market Trends
    • 6.4.2. Market Forecast
  • 6.5. Tricyclic Antidepressants
    • 6.5.1. Market Trends
    • 6.5.2. Market Forecast
  • 6.6. Monoamine Oxidase Inhibitors
    • 6.6.1. Market Trends
    • 6.6.2. Market Forecast
  • 6.7. Others
    • 6.7.1. Market Trends
    • 6.7.2. Market Forecast

7. Market Breakup by Disorder Type

  • 7.1. Major Depressive Disorder
    • 7.1.1. Market Trends
    • 7.1.2. Market Forecast
  • 7.2. Obsessive-Compulsive Disorder
    • 7.2.1. Market Trends
    • 7.2.2. Market Forecast
  • 7.3. Generalized Anxiety Disorder
    • 7.3.1. Market Trends
    • 7.3.2. Market Forecast
  • 7.4. Panic Disorder
    • 7.4.1. Market Trends
    • 7.4.2. Market Forecast
  • 7.5. Others
    • 7.5.1. Market Trends
    • 7.5.2. Market Forecast

8. Market Breakup by Drug Type

  • 8.1. Generic Drugs
    • 8.1.1. Market Trends
    • 8.1.2. Market Forecast
  • 8.2. Branded Drugs
    • 8.2.1. Market Trends
    • 8.2.2. Market Forecast

9. Market Breakup by Distribution Channel

  • 9.1. Hospital Pharmacies
    • 9.1.1. Market Trends
    • 9.1.2. Market Forecast
  • 9.2. Retail Pharmacies
    • 9.2.1. Market Trends
    • 9.2.2. Market Forecast
  • 9.3. Online Pharmacies
    • 9.3.1. Market Trends
    • 9.3.2. Market Forecast
  • 9.4. Others
    • 9.4.1. Market Trends
    • 9.4.2. Market Forecast

10. Market Breakup by Region

  • 10.1. North America
    • 10.1.1. Market Trends
    • 10.1.2. Market Forecast
  • 10.2. Europe
    • 10.2.1. Market Trends
    • 10.2.2. Market Forecast
  • 10.3. Asia Pacific
    • 10.3.1. Market Trends
    • 10.3.2. Market Forecast
  • 10.4. Middle East and Africa
    • 10.4.1. Market Trends
    • 10.4.2. Market Forecast
  • 10.5. Latin America
    • 10.5.1. Market Trends
    • 10.5.2. Market Forecast

11. SWOT Analysis

  • 11.1. Overview
  • 11.2. Strengths
  • 11.3. Weaknesses
  • 11.4. Opportunities
  • 11.5. Threats

12. Value Chain Analysis

13. Porter's Five Forces Analysis

  • 13.1. Overview
  • 13.2. Bargaining Power of Buyers
  • 13.3. Bargaining Power of Suppliers
  • 13.4. Degree of Competition
  • 13.5. Threat of New Entrants
  • 13.6. Threat of Substitutes

14. Price Analysis

15. Competitive Landscape

  • 15.1. Market Structure
  • 15.2. Key Players
  • 15.3. Profiles of Key Players
    • 15.3.1. Otsuka Pharmaceutical
    • 15.3.2. Pfizer
    • 15.3.3. Eli Lilly and Company
    • 15.3.4. AstraZeneca
    • 15.3.5. Novartis
    • 15.3.6. Bristol-Myers Squibb
    • 15.3.7. GlaxoSmithKline
    • 15.3.8. Takeda Pharmaceutical Company
    • 15.3.9. Allergan
    • 15.3.10 Johnson & Johnson
    • 15.3.11 Zhejiang NHU Company Ltd
    • 15.3.12 Sebela Pharmaceuticals
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.